A Randomized, Blinded, Multicenter Trial of Lipid-Associated Amphotericin B Alone versus in Combination with an Antibody-Based Inhibitor of Heat Shock Protein 90 in Patients with Invasive Candidiasis | Zendy

Jan Pachl | Zendy; Petra Svoboda | Zendy; F. Jacobs | Zendy; K. Vandewoude | Zendy; Ben van der Hoven | Zendy; Peter E. Spronk | Zendy; Gary Masterson | Zendy; Manu L. N. G. Malbrain | Zendy; M. Aoun | Zendy; Jorge Garbino | Zendy; Jukka Takala | Zendy; Ľuboš Drgoňa | Zendy; J. Burnie | Zendy; Ruth Matthews | Zendy

Open Access

A Randomized, Blinded, Multicenter Trial of Lipid-Associated Amphotericin B Alone versus in Combination with an Antibody-Based Inhibitor of Heat Shock Protein 90 in Patients with Invasive Candidiasis

Author(s) -

Jan Pachl,

Petra Svoboda,

F. Jacobs,

K. Vandewoude,

Ben van der Hoven,

Peter E. Spronk,

Gary Masterson,

Manu L. N. G. Malbrain,

M. Aoun,

Jorge Garbino,

Jukka Takala,

Ľuboš Drgoňa,

J. Burnie,

Ruth Matthews

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/503428

Subject(s) - amphotericin b , medicine , placebo , candida albicans , gastroenterology , odds ratio , confidence interval , population , mycosis , randomized controlled trial , immunology , microbiology and biotechnology , antifungal , biology , pathology , dermatology , alternative medicine , environmental health

Mycograb (NeuTec Pharma) is a human recombinant monoclonal antibody against heat shock protein 90 that, in laboratory studies, was revealed to have synergy with amphotericin B against a broad spectrum of Candida species.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research